{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:31:47Z","timestamp":1787700707675,"version":"build-2784847793"},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.2169\/internalmedicine.5922-20","type":"journal-article","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T22:06:42Z","timestamp":1616969202000},"page":"3459-3462","source":"Crossref","is-referenced-by-count":26,"title":["Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer"],"prefix":"10.2169","volume":"60","author":[{"given":"Makiko","family":"Yomota","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kie","family":"Mirokuji","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Collagen Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Setoguchi","sequence":"additional","affiliation":[{"name":"Department of Collagen Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158-168, 2018.","DOI":"10.1056\/NEJMra1703481"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15: 47-62, 2018.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23: 943-947, 2018.","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124: 188-195, 2014.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378: 2288-2301, 2018.","DOI":"10.1056\/NEJMoa1716948"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378: 2078-2092, 2018.","DOI":"10.1056\/NEJMoa1801005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shimabukuro-Vornhagen A, Godel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer 6: 56, 2018.","DOI":"10.1186\/s40425-018-0343-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Michael L. Adashek a, d Marvin Feldman. Cytokine Release Syndrome Resulting From Anti-Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists. J Oncol Pract 15: 502-505, 2019.","DOI":"10.1200\/JOP.19.00160"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kogure Y, Ishii Y, Oki M. Cytokine release syndrome with pseudoprogression in a patient with advanced non-small cell lung cancer treated with pembrolizumab. J Thorac Oncol 14: e55-e57, 2019.","DOI":"10.1016\/j.jtho.2018.11.025"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12: 259-268, 2016.","DOI":"10.1038\/nrrheum.2015.179"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_5922-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T03:18:30Z","timestamp":1636168710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_5922-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":10,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5922-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"5922-20"}}